Corvus Pharmaceuticals To Present At SITC's 31st Annual Meeting

BURLINGAME, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it will present preliminary clinical and biomarker data from its from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech's TECENTRIQ® (atezolizumab), at the Society for Immunotherapy of Cancer's (SITC) 31 st Annual Meeting & Associated Programs taking place November 9 - 13 in National Harbor, Maryland.

Following are the details of Corvus' two poster presentations:
  • Phase 1/1b multicenter trial of CPI-444, an adenosine A2a receptor (A2aR) antagonist as a single agent and in combination with atezolizumab (atezo) in patients with advanced solid tumors (Poster #149)

Authors: John Powderly II 1 (presenter), Joshua Brody 2, John Nemunaitis 3, Leisha Emens 4, Jason J. Luke 5, Amita Patnaik 6, Ian McCaffery 7, Richard Miller 7, Ginna Laport 7 Affiliations: 1Carolina BioOncology Institute, Huntersville, NC; 2Mount Sinai School of Medicine, New York, NY; 3Mary Crowley Cancer Research Center, Gradalis, Inc., Medical City Dallas Hospital, Baylor University Medical Center, Dallas, TX; 4Johns Hopkins School of Medicine, Baltimore, MD; 5University of Chicago School of Medicine; 6 South Texas Accelerated Research Therapeutics, San Antonio, TX, 7Corvus Pharmaceuticals, Burlingame, CA

Session Date and Time: Friday, November 11, 12:15 - 1:30 p.m. and 6:15 - 7:30 p.m. ET

Location: Gaylord National Hotel & Convention Center, Prince George's Exhibition Hall AB
  • CPI-444: a potent and selective inhibitor of adenosine 2A receptor (A2AR) induces anti-tumor responses alone and in combination with anti-PD-L1 (Poster #218)

If you liked this article you might like

16 Biopharma Companies Besides Medivation That Are Attractive Targets